BioVie (BIVI) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Theriva Biologics (TOVX) over the past year, losing 28.7% versus a loss of 49.5%. Over five years, BIVI leads with a -99.8% price change compared with -99.8% for TOVX. BioVie is the larger company by market cap ($12.1 million vs $10.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | TOVX |
|---|---|---|
| Share price | $1.39 | $0.217 |
| Market cap | $12.07M | $9.96M |
| 1-day change | +8.59% | -4.45% |
| YTD return | +19.83% | +8.14% |
| 1-year return | -28.72% | -49.53% |
| 5-year return | -99.76% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-3.05 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $0.86 |
| 52-week low | $0.82 | $0.16 |
| Distance from 52-week high | -63.32% | -74.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +278.42% | +1052.07% |
| Average volume | 4.60M | 525.96K |
| Shares outstanding | 8.68M | 45.89M |
| Employees | 13 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed TOVX by 20.8 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
BIVI vs TOVX FAQ
Which is bigger, BioVie or Theriva Biologics?
BioVie (BIVI) is larger, with a market capitalization of $12.07M compared with $9.96M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, BIVI or TOVX?
BIVI returned -28.72% over the past 12 months, compared with -49.53% for TOVX (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.